Literature DB >> 16123586

Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.

Thomas Helleday1, Helen E Bryant, Niklas Schultz.   

Abstract

Poly(ADP-ribose) polymerase (PARP-1) binds to DNA breaks to facilitate DNA repair. However, the role of PARP-1 in DNA repair appears to not be critical since PARP-1 knockout mice are viable, fertile and do not develop early onset tumors. Cells isolated from these mice show an increased level of homologous recombination. There is an intricate link between homologous recombination and PARP-1 and a possible role for PARP-1 in DNA double-strand break repair. Although PARP-1 appears not to be required for homologous recombination itself, it regulates the process through its involvement in the repair of DNA single-strand breaks (SSBs). SSBs persisting into the S phase of the cell cycle collapse replication forks, triggering homologous recombination for replication restart. We discuss the recent discoveries on the use of PARP-1 inhibitors as a targeted cancer therapy for recombination deficient cancers, such as BRCA2 tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123586     DOI: 10.4161/cc.4.9.2031

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  74 in total

1.  ZNF365 promotes stalled replication forks recovery to maintain genome stability.

Authors:  Yuqing Zhang; Eunmi Park; Christopher S Kim; Ji-hye Paik
Journal:  Cell Cycle       Date:  2013-08-06       Impact factor: 4.534

Review 2.  BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability.

Authors:  Amal Aly; Shridar Ganesan
Journal:  J Mol Cell Biol       Date:  2011-02       Impact factor: 6.216

Review 3.  PARP-1 and its associated nucleases in DNA damage response.

Authors:  Yijie Wang; Weibo Luo; Yingfei Wang
Journal:  DNA Repair (Amst)       Date:  2019-07-08

4.  ART1 promotes starvation-induced autophagy: a possible protective role in the development of colon carcinoma.

Authors:  Yi Tang; Ming Li; Ya-Lan Wang; Michael D Threadgill; Ming Xiao; Chun-Feng Mou; Guang-Lin Song; Jing Kuang; Xi Yang; Li Yang; Xing-Jie Gao; Ya-Ping Wang; Yun-Peng Meng
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

Review 5.  Update on familial pancreatic cancer.

Authors:  Ralph H Hruban; Marcia I Canto; Michael Goggins; Richard Schulick; Alison P Klein
Journal:  Adv Surg       Date:  2010

6.  Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.

Authors:  Aiste McCormick; Peter Donoghue; Michelle Dixon; Richard O'Sullivan; Rachel L O'Donnell; James Murray; Angelika Kaufmann; Nicola J Curtin; Richard J Edmondson
Journal:  Clin Cancer Res       Date:  2016-10-04       Impact factor: 12.531

Review 7.  BRCA1 Mutation: A Predictive Marker for Radiation Therapy?

Authors:  Charlene Kan; Junran Zhang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-10-01       Impact factor: 7.038

Review 8.  New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Authors:  Susanne Burdak-Rothkamm; Kevin M Prise
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

9.  BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Authors:  Pierosandro Tagliaferri; Monica Ventura; Francesco Baudi; Iole Cucinotto; Mariamena Arbitrio; Maria Teresa Di Martino; Pierfrancesco Tassone
Journal:  J Ovarian Res       Date:  2009-10-13       Impact factor: 4.234

Review 10.  Non-homologous end joining in class switch recombination: the beginning of the end.

Authors:  Ashwin Kotnis; Likun Du; Chonghai Liu; Sergey W Popov; Qiang Pan-Hammarström
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-03-12       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.